Arrowhead Pharmaceuticals, Inc. (ARWR)
Nasdaq: ARWR · Pharmaceutical Preparations · Pasadena, CA · filing with the SEC since 1998
Who owns Arrowhead Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
4
Blackrock, Inc. holds 10.1% of Common Stock, as its SCHEDULE 13G/A filed Jul 27, 2026 says.
Directors and officers
12
report now, of 24 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 27, 2026 · Common Stock · 12.2% in Apr 24, 2026
Avoro Capital Advisors LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share · 8.3% in Aug 14, 2025
Fmr LLC
SCHEDULE 13G · filed May 6, 2026 · COMMON STOCK
Vanguard Capital Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
State Street Corporation
SCHEDULE 13G · filed Aug 11, 2025 · COMMON STOCK · reported falling below 5%, from 5.1% in May 13, 2025
Vanguard Portfolio Management
SCHEDULE 13G/A · filed Jul 31, 2026 · Common Stock · reported falling below 5%, from 5.19% in Apr 28, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 11.2% in Jul 29, 2025
Sarepta Therapeutics, Inc.
SCHEDULE 13D/A · filed Aug 15, 2025 · Common stock, par value $0.001 per share (the "Common Stock") · reported falling below 5%, from 9.5% in Feb 14, 2025
What ARWR reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Novartis
A company bought · asset acquisition · owns, named in the 10-K filed Nov 25, 2025
5 subsidiaries in 4 countries, from the list filed with the 10-K filed Nov 25, 2025.
Insider tradesForm 4
65sales
0purchases
45sales on a scheduled plan
10people selling
$38.0Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window10 of 24 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Anzalone Christopher Richard | Chief Executive Officer | 25 | $24.0M | 9 | 0 | $0 |
| Hamilton James C | Chief Medical Officer | 10 | $4.6M | 10 | 0 | $0 |
| O'Brien Patrick | COO | 12 | $3.1M | 12 | 0 | $0 |
| Perry Michael S | director | 2 | $2.0M | 0 | 0 | $0 |
| Ferrari Mauro | director | 2 | $1.0M | 1 | 0 | $0 |
| Apel Daniel Joseph | Chief Financial Officer | 3 | $900,000 | 3 | 0 | $0 |
| Olukotun Adeoye Y | director | 4 | $900,000 | 3 | 0 | $0 |
| Vakiener Victoria | director | 3 | $700,000 | 3 | 0 | $0 |
| Waddill William D. | director | 3 | $600,000 | 3 | 0 | $0 |
| Lu Hongbo | director | 1 | $200,000 | 1 | 0 | $0 |